Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Pharma And Distributors Suffer From Essential Drug System And Price Cuts

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - While many investors are looking forward to a rebound in the second half of 2011 following a disappointing first half, analysts from Morgan Stanley poured cold water on investor hopes in Hong Kong by downgrading pharma and distribution sectors in a July 7 research note
Advertisement

Related Content

As Initial Healthcare Reform Period Closes, China Allows More High-Price Drugs In Community Clinics
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
Advertisement
UsernamePublicRestriction

Register

SC078462

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel